Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buprenorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 14/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 10/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buprenorphine SCHEMBL24145260 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24145376 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24846187 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24437360 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL23647314 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24145377 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24171581 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL23629525 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL24145658 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 | |
| Buprenorphine SCHEMBL23702715 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153739-A1 | OPIOID RECEPTOR MODULATOR AND USE THEREOF | ARRIBA BIOPHARMA, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153739-A1 | OPIOID RECEPTOR MODULATOR AND USE THEREOF | OPRD1, OPRM1, OPRL1 | OPRK1 4/4885OPRM1 2/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.